Retrospective US Database Analysis of Persistence With Glatiramer Acetate vs. Available Disease-Modifying Therapies for Multiple Sclerosis: 2001–2010 MerriKay Oleen-Burkey; Anissa Cyhaniuk; Eric ...

Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone ® 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple ...

Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes Zydus Lifesciences Limited ...

Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone ® 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling 911 if you experience symptoms of an anaphylactic reaction, FDA warned.

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is associated with a risk for anaphylaxis and issued a new boxed warning ...

If an optional autoinjector is used for administration, patients should ensure the device is compatible for use with their specific glatiramer acetate product. The labels for glatiramer acetate ...

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting ...

Mapi Pharma Ltd. announced today it will host a key opinion leader webinar on Glatiramer Acetate (GA) Depot, a potential long-acting injection solution for multiple sclerosis (MS) patients, on ...